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Neurological and psychiatric disorders are frequently associated with disruption of various
cognitive functions, but development of effective drug treatments for these conditions
has proven challenging. One of the main obstacles is the poor predictive validity of our
preclinical animal models. In the present study the effects of the γ-secretase inhibitor
semagacestat was evaluated in preclinical in vivo electrophysiological models. Recently
disclosed Phase III ﬁndings on semagacestat indicated that Alzheimer’s disease (AD)
patients on this drug showed signiﬁcantly worsened cognitive function compared to those
treated with placebo. Since previous studies have shown that drugs impairing cognitive
function (including scopolamine, NMDA (N -methyl-D-aspartate) receptor antagonists, and
nociceptin receptor agonists) disrupt or decrease power of elicited theta oscillation in
the hippocampus, we tested the effects of acute and sub-chronic administration of
semagacestat in this assay. Field potentials were recorded across the hippocampal
formation with NeuroNexus multi-site silicon probes in urethane anesthetized male
C57BL/6 mice; hippocampal CA1 theta oscillation was elicited by electrical stimulation
of the brainstem nucleus pontis oralis. Sub-chronic administration of semagacestat twice
daily over 12 days at a dose known to reduce beta-amyloid peptide (Aβ) level [100mg/kg, p.o.
(per oral)] diminished power of elicited hippocampal theta oscillation. Acute, subcutaneous
administration of semagacestat (100 mg/kg) produced a similar effect on hippocampal
activity. We propose that the disruptive effect of semagacestat on hippocampal function
could be one of the contributing mechanisms to its worsening of cognition in patients with
AD. As it has been expected, both acute and sub-chronic administrations of semagacestat
signiﬁcantly decreased Aβ40 and Aβ42 levels but the current ﬁndings do not reveal the
mode of action of semagacestat in disrupting hippocampal oscillation.
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INTRODUCTION
Neurological and psychiatric disorders are frequently associated
with disruption of various cognitive functions, but development
of effective drug treatments for these conditions has proven chal-
lenging. One of the main obstacles is the poor predictive validity
of our preclinical animal models; drugs showing improved cogni-
tive function in behavioral rodent models often fail in the clinics,
in part due to the shortcomings of modeling disease pathology in
experimental animals.
Using in vivo electrophysiological assays, previous studies have
shown that drugs impairing cognitive function, such as scopo-
lamine, NMDA (N-methyl-D-aspartate) receptor antagonists and
nociceptin receptor agonists disrupt or decrease power of elicited
theta oscillation in the hippocampus of anesthetized rats (Kin-
ney et al., 1999; Siok et al., 2006; Li et al., 2007; McNaughton
et al., 2007; Hajós et al., 2009; Kittelberger et al., 2012) or mice
(Guadagna et al., 2012; Kiss et al., 2013). Furthermore, in trans-
genic mice capturing some pathology of a neurological or psy-
chiatric disease and showing cognitive impairment power of
elicited hippocampal theta is signiﬁcantly reduced, including the
beta-amyloid peptide (Aβ) overproducing amyloid precursor pro-
tein (APP)/PS1transgenic mice, tau-transgenic mice and NMDA
receptor hypomorphic mice (Scott et al., 2011, 2012; Kiss et al.,
2013). In contrast, those few drugs which improve cognitive func-
tion in patients, including acetylcholine esterase inhibitors and
memantine increase the power of elicited theta oscillation in this
assay (Kinney et al., 1999; Guadagna et al., 2012).
In the present study the effects of theγ-secretase inhibitor (GSI)
semagacestat has been evaluated in this preclinical hippocampal
theta model. One of the distinguishing features of Alzheimer’s dis-
ease (AD) pathology is deposition of Aβ containing senile plaques
in the brains of patients. According to the amyloid hypothesis,
increased production or decreased clearance and degradation of
Aβ initiates a molecular cascade ultimately leading to neurode-
generation and the clinical manifestation of cognitive decline and
senile dementia. The generation of Aβ requires sequential cleav-
age of the type I integral membrane APP by β then γ-secretase
(Imbimbo and Giardina, 2011). Semagacestat, by inhibiting γ-
secretase reduces level of Aβ in Alzheimer’s patients (Bateman
et al., 2009; Mancuso et al., 2011), therefore it was predicted that
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it could either improve cognitive function and/or slow down dis-
ease progression. However, recently disclosed Phase III ﬁndings
on semagacestat indicated that AD patients on this drug showed
signiﬁcantly worsened cognitive function to those treated with
placebo (Schor, 2011). In our studies, we evaluated the effects
of semagacestat on hippocampal theta oscillation in normal mice
(C57/BL/6), both after sub-chronic and acute administrations. For
sub-chronic treatment of semagacestat, mice received oral drug
treatment at 100 mg/kg dose, twice daily over 12 days; electro-
physiological recordings were carried out 3 h after the last drug
administration. Acute effects of semagacestat were also evaluated
after subcutaneous administration of semagacestat (100 mg/kg).
After completion of experiments brain samples were collected for
Aβ level measurements; drug exposure levels were determined
from both plasma and brain samples.
MATERIALS AND METHODS
SURGICAL PROCEDURES AND ELECTROPHYSIOLOGICAL RECORDINGS
Male C57BL/6 mice were anesthetized with 1.5–1.7 g/kg urethane
intraperitoneally, under an approved animal use protocol and in
compliancewith theAnimalWelfareActRegulations [9CFR (Code
of Federal Regulations) parts 1, 2, and 3] andwith theGuide for the
Care and Use of Laboratory Animals, National Institutes of Health
guidelines. The animals were placed in a Kopf stereotaxic frame
on a temperature regulated heating pad (Harvard Apparatus) set
to maintain body temperature at 37–38 ◦C.
STIMULATION-EVOKED HIPPOCAMPAL THETA OSCILLATION
A 16-site silicon recording electrode (A1x16-10mm-100-177-T15
NeuroNexus Technologies, Inc, Ann Arbor, MI, USA) was acutely
implanted to span the hippocampal formation, placed 2.0 mm
posterior from and 1.5 mm lateral to bregma and the tip slowly
lowered 1.9 mm from the cortical surface (Paxinos and Franklin,
2001). As a ﬁrst step, population spikes in the dentate gyrus
were recorded in response to stimulation of perforant path (co-
ordinates of stimulating electrode:: 0.5mmanterior to and 2.5mm
lateral to lambda and 1.4–1.9 mm from cortical surface) using a
concentric bipolar electrode (NE-100X, Rhodes Medical Instru-
ments, Woodland Hills, CA, USA) in order to position recording
electrodes consistently in all mice, as we reported previously (Scott
et al., 2012). Subsequently, the same stimulating electrode was
positioned to the nucleus pontis oralis (nPO), 4.0 mm posterior
and 1.2 mm lateral from bregma and 3.3 mm ventral from cortical
surface. Stimulation consisted of a train of 0.3 ms square pulses
delivered over 6 s at 250 Hz, repeated every 100 s (Figure 1).
Stimulus intensities were either held constant for time course
experiments or increased in a step-wise fashion (see below). Dur-
ing each experiment, spontaneous and stimulation-induced local
ﬁeld potentials were continuously monitored, data was digitized
at 1 kHz using the A-M System (Carlsborg, WA, USA) and Spike2
software package (CambridgeElectronicDesign,Cambridge,UK).
Among the 4 out of 16 channels located in the CA1 region one
channel was selected in this study for further analysis and statistics.
Comparing theta activity in mice sub-chronically treated with
vehicle or semagacestat stimulus-response curves were obtained
using increasing stimulus intensities of 0.00–0.20 mA in 0.02 mA
increments, 3 h after last oral drug administration. Input–output
curves were generated by repeating this stimulation paradigm ﬁve
times per animal; the last three measurements were averaged for
analysis. Acute effects of semagacestat were tested following deter-
mination of stimulus-response relationship for both peak theta
frequency and total theta power for each mouse. Stimulating cur-
rent necessary to induce hippocampal theta oscillation between 5
and 8 Hz with an absolute power between 60 and 80% of the max-
imal response was used for time course experiments as described
in detail earlier (Siok et al., 2006).
ELECTROPHYSIOLOGICAL DATA ANALYSIS AND STATISTICS
For nPO stimulation-evoked hippocampal theta oscillation Fast
Fourier transformation (FFT) was performed on each 6 s stim-
ulation period, using 1–5.096 s (0.25 Hz frequency resolution)
following stimulation onset, to avoid inclusion of stimulation arti-
fact in analysis. Peak frequency and total power in the theta band
(3–12Hz)were determined. For visual assessment of the composi-
tion of hippocampal oscillations short-time FFTs were calculated.
Frequencies between 0.25 and 10 Hz were evaluated by a 0.05 Hz
frequency step. To decrease granularity of the resulting high-
resolution ﬁgures data was smoothed using a two-dimensional
square function of 1 s × 0.5 Hz size. These calculations were per-
formed in Matlab (R2009a, MathWorks, Inc, Natick, MA, USA).
For statistical evaluation of data either GraphPad Prism (Graph-
Pad Software, Inc, La Jolla, CA, USA) or the Matlab Statistics
Toolbox (v7.1, R2009a, MathWorks, Inc, Natick, MA, USA) was
used.
BIOCHEMISTRY
Homogenization of brain tissue
Frozen C57BL/6 brain tissue was homogenized in 10 volumes of
5 M guanidine-HCl, pH 8 (Sigma-Aldrich, St Louis, MO, USA)
using aTissue Lyser II (Qiagen,Germantown,MD,USA) and incu-
bated for 3 h at room temperature. The guanidine homogenate
was centrifuged at 116,000 × g for 1 h, 4◦C. The resulting super-
natant was applied to 60 mg HLB 96-well plates (Waters, Milford,
MA, USA) and concentrated as described previously (Lanz and
Schachter, 2006). The resulting lyophilized pellets were stored at
−80◦C prior to resuspension in blocking buffer for analysis by the
DELFIA Aβ ELISA.
DELFIA AβELISA
Resuspended brain tissue lysates were incubated in 384-well black
plates prepared as follows. 384-well black plates (VWR, Bridge-
port, NJ, USA) were coated overnight at 4◦C with a C-terminal-
speciﬁc anti-Aβ40 (4 μg/ml), and an anti-Aβ42 (10 μg/ml; Rinat,
South San Francisco, CA, USA), diluted in 0.1 M sodium bicar-
bonate, pH 8.2. The next day plates were washed and then blocked
for 2–4 h at room temperature with 1% bovine serum albumin in
phosphate buffered saline with 0.05% Tween 20 (Sigma-Aldrich,
St. Louis, MO, USA). Standard curves were prepared from stock
solutions of species-speciﬁc Aβ peptides (Bachem Biosciences,
King of Prussia, PA, USA) in blocking buffer. Standards and sam-
ples were incubated on the coated and blocked 384-well plates
overnight at 4◦C. Plates were washed and a secondary biotinylated
4G8 (0.2 μg/ml; Covance, Dedham, MA, USA) was incubated for
2 h at room temperature. The signal was ampliﬁed by incubation
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FIGURE 1 | Summary of the protocol used in the present study: electrical
stimulation of the brainstem nucleus pontis oralis (nPO; with increasing
current intensity between first and second simulation; indicated as Stim
on and Stim off) elicited rhythmic oscillation of hippocampal local field
potential (LFP) in theta frequency; recordings were carried out across the
hippocampal formation; LFP from the hippocampus CA1 region was
analyzed in the present study. Following fast Fourier transformation (FFT) of
the LFP frequency of the highest power component (Peak frequency), and
total power in the theta frequency band (3–12 Hz) were recorded for each
stimulation period.
with europium-conjugated streptavidin for 1 h at room tempera-
ture followed by incubation with DELFIA enhancement solution
at room temperature for 20 min in the dark. Plates were read on
anEnVisionMultilabel plate reader (europium-Delﬁa reagents and
equipment from PerkinElmer Life Sciences, Boston, MA, USA).
Standard values were ﬁt to a fourth-order polynomial curve, and
sample values were extrapolated using GraphPad Prism 5.02 (La
Jolla, CA, USA).
DRUGS
For acute administration semagacestat (LY450139, synthesized at
Pﬁzer, Inc.,Groton,CT,USA) 100mg/kg or vehicle (Phosal/Tween,
12/88) were injected subcutaneous (s.c.) after 30 min of stable
baseline recording. For sub-chronic administration semagacestat
100 mg/kg or vehicle (20%PEG/20%Solutol) were administered
per oral (p.o.) twice daily with last drug application done 3 h
before the start of recording.
MEASUREMENT OF DRUG LEVELS IN THE BRAIN AND PLASMA
Semagacestat exposure was determined after completion of the
electrophysiological measurements, 5 h following the last oral
administration of semagacestat in the sub-chronic study, or 3 h
after its subcutaneous injection. Concentration of semagacestat
was determined using liquid chromatography-tandem mass spec-
trometry following the method reported previously (Lanz et al.,
2006).
RESULTS
REDUCED POWER OF ELICITED HIPPOCAMPAL THETA OSCILLATION IN
RATS SUB-CHRONICALLY TREATED WITH SEMAGACESTAT
Electrical stimulation of the nPO elicited highly regular hip-
pocampal oscillations whose frequency and amplitude increased
proportionally to the stimulus intensity in vehicle-treatedC57BL/6
mice (twice daily 100 mg/kg, p.o. over 12 days, n = 4), as
shown previously in both anesthetized rats and mice (Kinney
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et al., 1999; Siok et al., 2006; McNaughton et al., 2007; Scott
et al., 2012; Kiss et al., 2013). Sub-chronic administration of
semagacestat (n = 4) signiﬁcantly attenuated power of hip-
pocampal theta oscillation across the entire theta frequency range
(p < 0.05) as measured 3 h following the last orally adminis-
tered dose of semagacestat. Comparing baseline level of absolute
theta power, increasing stimulation currents failed to elicit higher
theta power (Figure 2A), and relative theta power stayed at the
same range as well (Figure 2B). In contrast, increasing stim-
ulating current induced the same increase in theta frequency
FIGURE 2 | Sub-chronic administration of semagacestat (twice daily
100 mg/kg, p. o. over 12 days, n = 4, RED symbols) significantly
attenuated absolute (A) and relative (B) power of hippocampal theta
oscillation elicited by stimulation of the nucleus pontis oralis with
increasing currents (0–0.2 mA) compared to vehicle-treated control
C57BL/6 mice (n = 4; BLUE symbols; *p < 0.05). In contrast, no
signiﬁcant difference in peak frequency in elicited theta activity was
noticed (C).
between vehicle- and semagacestat-treated mice, in fact there
was a trend to augmented theta frequency in semagacestat-
treatedmice at higher stimulation currents/higher frequency range
(Figure 2C).
ACUTE ADMINISTRATION OF SEMAGACESTAT REDUCES POWER OF
ELICITED HIPPOCAMPAL THETA OSCILLATION
Effects of acutely administered semagacestat were also evaluated
on stimulation-induced hippocampal theta oscillation. In these
experiments, stimulating current was determined in each indi-
vidual mouse by establishing a stimulus-response relationship;
and current inducing theta oscillation between 5 and 8 Hz fre-
quency with an absolute power between 60 and 80% of the
maximal response was selected. For inter-animal comparisons,
total theta power during nPO stimulation was normalized for
each mouse to the average power measured prior to drug or
vehicle administration. Following 30 min baseline recordings
semagacestat (100 mg/kg, s.c, n = 5) or it vehicle (n = 6)
was given and stimulation-induced theta oscillation followed up
to 3 h. As it has been expected, power of stimulation-induced
theta gradually decreased through the recording period, how-
ever, semagacestat-treated mice showed a signiﬁcantly greater
reduction in theta power then vehicle-treated mice(*p < 0.05;
Figure 3). Time-frequency decomposition of representative hip-
pocampal recordings also indicated that power of spontaneous
hippocampal ﬁeld potential shifted to lower (<2Hz) frequen-
cies, and nPO stimulation did not elicit the regular 4–5 Hz
theta rhythm, as it is demonstrated on Figure 4. No signiﬁ-
cant difference in peak frequency in elicited theta activity was
noticed between drug and vehicle-treated mice, although a clear
trend for an increase in frequency in semigacestat-treated mice
was noticed at approximately 90 min after drug administration
(Figure 3B).
BOTH SUB-CHRONIC AND ACUTE ADMINISTRATIONS OF
SEMAGACESTAT SIGNIFICANTLY REDUCED BRAIN Aβ SPECIES
Beta-amyloid peptide levels, extracted from C57BL/6 mouse brain
homogenates acutely or sub-chronically treated with semagaces-
tat, were measured using DELFIA TRF technology. The resulting
Aβ lowering in the sub-chronically dosed mice were observed
to be signiﬁcant at 51% for Aβ40 and 26% for Aβ42 compar-
ing to vehicle-treated mice, approximately 4–5 h after last oral
drug administration and on completion of the electrophysiologi-
cal recording (Figure 5A). Acutely treated mice (100 mg/kg, s.c.)
had an even greater reduction in Aβspecies after completion of the
electrophysiological recordings, and 3 h after drug administration,
showing a high level statistical signiﬁcance, as a 65% lowering of
Aβ40 and a 31% reduction of Aβ42. Note the greater lowering of
Aβ40 with respect to Aβ42 in both the acute and sub-chronically
treated mice. This reﬂects an apparent GSI-induced increase in the
ratio of Aβ42 to Aβ40 (Figure 5B).
PLASMA AND BRAIN EXPOSURE OF SEMAGACESTAT
Completion of the electrophysiological recording blood and
brain samples were taken for determining levels of semagaces-
tat. Both sub-chronic and acute s.c. administration resulted in
the expected range of drug exposure in mice. Unbound brain
Frontiers in Pharmacology | Experimental Pharmacology and Drug Discovery June 2013 | Volume 4 | Article 72 | 4
“fphar-04-00072” — 2013/6/14 — 14:59 — page 5 — #5
Hajós et al. Reduction in hippocampal theta by semagacestat
FIGURE 3 | Acute administration of semagacestat (100 mg/kg, s. c,
n = 5, RED symbols) significantly (*p < 0.05) attenuated power
of elicited hippocampal theta oscillation (A) compared to vehicle-treated
control C57BL/6 mice (n = 6, BLUE symbols) as followed in time.
No signiﬁcant difference in peak frequency in elicited theta activity was
noticed (B).
FIGURE 4 |Time-frequency decomposition of representative
hippocampal recordings from two mice treated with vehicle (A,B) or
semagacestat (100 mg/kg; C,D) approximately 30 min after start of
recordings as indicated by white arrows. Note the strong and persistent
low frequency (<2 Hz) component of the ongoing oscillation pattern in the
semagacestat-treated animals, which unlike in the case of vehicle-treated
animals does not give place to the regular 4–5 Hz theta rhythm during
stimulation periods.
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FIGURE 5 | Both sub-chronic treatment (A, twice daily, 100 mg/kg,
p. o. over 12 days) and acute treatment (B, 100 mg/kg, s.c.) with
semagacestat (Smg) significantly reduced brain Aβ levels compared
to vehicle-treated controls.
compound concentrations were 0.14 + 0.03 and 4.9 + 0.5 μM;
unbound plasma compound concentrations were 1.6 + 0.04 and
51 + 10 μM following sub-chronic and acute administration of
semagacestat, respectively. Blood/plasma ratio of 0.12 is similar
to previously reported value obtained in guinea-pigs (Lanz et al.,
2006).
DISCUSSION
Both sub-chronic and acute treatment of anesthetized mice with
the GSI semagacestat signiﬁcantly impacted stimulation-induced
hippocampal theta activity, primarily reducing power of theta
oscillation. This effect is characteristic of drugswhich are known to
disrupt cognitive function in humans or animal models. Although
both sub-chronic and acute semagacestat treatments signiﬁcantly
reduced brain Aβ40 and Aβ42 levels, the exact mechanism(s)
underlying the currently described neurophysiological effect of
semagacestat is unknown at the present.
In line with previous studies, high frequency stimulation
of the nPO elicited hippocampal theta oscillation, character-
ized by a current-dependent increase in both theta frequency
and theta power in vehicle-treated mice (Guadagna et al., 2012;
Scott et al., 2012; Kiss et al., 2013). Mice treated sub-chronically
with semagacestat showed a similar current-dependent increase
in theta frequency to those mice treated with vehicle; however,
the power of theta oscillation was signiﬁcantly reduced. Com-
paring either absolute or relative theta power between vehicle-
and semagacestat-treated mice, signiﬁcant differences were found
over the entire theta frequency range. In fact, current-dependent
increase in theta power was almost absent in animal pretreated
with semagacestat. Furthermore, single administration of sema-
gacestat at a dose (100 m/kg, sc) known to acutely reduce
brain Aβ peptides (Lu et al., 2012) resulted in a signiﬁcantly
greater reduction in theta power than acute administration of
its vehicle. Interestingly, there was a tendency for increasing
theta frequency following either sub-chronic or acute adminis-
tration of semagacestat, although these differences did not reach
signiﬁcant levels. Since a reduction in elicited theta power has
been demonstrated by each and every drug known to impair
cognition, regardless of their mode of action (for review see
McNaughton et al., 2007), we propose that the presently observed
effect underlies, at least in part, the observed worsening of clin-
ical measures of cognition and the ability to perform activities
of daily living of Alzheimer’s patients treated with semagaces-
tat (Schor, 2011). In fact, semagacestat has been reported to
impaired normal cognition in wild-type mice and young Aβ over-
producing Tg2576 mice measured in Y-maze task (Mitani et al.,
2012). As power of theta oscillation reﬂects synchronous activ-
ity among hippocampal pyramidal neurons, it is presumed that
drugs reducing power of theta oscillation disrupt ﬁne tuning of
pyramidal neurons and subsequently impairs cognitive function.
For example, it has been shown that cannabinoid-1 receptors
agonists disrupt temporal coordination of cell assemblies in the
hippocampus, which is reﬂected in disrupted spontaneous or
stimulation-induced theta oscillation and leads tomemory deﬁcits
(Robbe et al., 2006; Hajós et al., 2008; Hajós and Siok, unpublished
observations).
As it has been predicted, both sub-chronic and acute admin-
istration of semagacestat reduced Aβ species in a fashion known
to be characteristic of GSIs (Bateman et al., 2009; Lu et al., 2012).
However, it is unknown at themoment if Aβ reduction contributes
to the diminished hippocampal theta oscillation. Since recent
ﬁndings indicate a physiological role of Aβ peptides in synap-
tic neurotransmission underlying learning and memory (Pearson
and Peers, 2006; Morley et al., 2010), this possibility cannot be
ruled out. Although microinjection of Aβ into the hippocampus
impairs behavioral performance and the associated hippocampal
theta oscillation (Villette et al., 2010), and elicited hippocampal
theta oscillation is age-dependently disrupted in Aβ overproduc-
ing APP/PS1 mice (Scott et al., 2012) indicating a synaptic failure
(Selkoe, 2002), recent ﬁndings also demonstrate a more complex
mechanism of Aβ action on neuronal excitability (Busche et al.,
2012; Mucke and Selkoe, 2012; Verret et al., 2012). Testing addi-
tional GSIs in this electrophysiological assay would address the
question whether reduction in Aβ via inhibition of γ-secretase
impacts hippocampal theta oscillation and impairs cognitive func-
tion. Furthermore, impact of Aβ reduction on hippocampal theta
oscillation by compounds acting via different mechanisms, such
as γsecretase modulators, Aβ antibodies, or β-secretase inhibitors
would be also informative, as diverse treatments differently change
composition of Aβ species andAPP cleavage products in the brain.
For example, differences in levels of the β-C-terminal fragment
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(β-CTF) of APP following GSIs and a γ-secretase modulator was
considered as a critical factor in their effect on cognition: the GSI
semagacestat increased β-CTF level and impaired cognitive func-
tion in wild-type mice whereas a second-generation γ-secretase
modulator neither increased β-CTF level nor impaired cognition
(Mitani et al., 2012). In addition to its role in generationof Aβ from
APP,γ-secretase also cleaves>80 discrete substrates,many of them
critical components of cell signaling, including Notch, ErbB4, E-
and N-cadherins, CD44, CD46, the low-density lipoprotein recep-
tor, Nectin-1, and the Notch ligands Delta and Jagged (Haapasalo
and Kovacs, 2011). Whether inhibition of the processing of any of
these substrates results in impaired signaling that could lead to the
detrimental cognitive effects observed in the semagacestat clinical
trial is thus far unknown.
It is also a possibility that reduction in elicited hippocampal
theta oscillation is an off-target effect of semagacestat, indepen-
dent from its Aβ reducing action. Since sub-chronic adminis-
tration of semagacestat maximally inhibited stimulation-induced
theta power without reduction in frequency, the 10-times higher
brain concentration of semagacestat following acute, s.c. adminis-
tration elicited similar effects and did not impact theta frequency
either. The short-onset effect of semagacestat following acute
administration is similar to those responses which are recorded
after application of direct-acting receptor antagonists, such as
the muscarinic or NMDA receptor antagonists (Kinney et al.,
1999; Siok et al., 2006; Li et al., 2007; McNaughton et al., 2007;
Guadagna et al., 2012; Kittelberger et al., 2012; Kiss et al., 2013).
The muscarinic receptor antagonist atropine reduces elicited theta
oscillation predominantly at lower but not higher frequency range
(Li et al., 2007), whereas the NMDA receptor antagonists ketamine
attenuates theta power across the whole theta frequency range
(Kittelberger et al., 2012) as semagacestat did in the present study.
However, receptor-binding studies on semagacestat did not reveal
an obvious or probable off-target of semagacestat for this effect
(CEREP proﬁle, Pﬁzer in-house database).
Testing stimulation-induced theta oscillation is considered as
a valuable pharmacodynamic assay with high predictive valid-
ity of cognitive disruption, but it provides limited information
about modulation of physiological hippocampal theta activity.
Hippocampal theta oscillation is present during active wakeful-
ness and orientation and rapid eye movement sleep, as well as
it plays a role in memory encoding and affective functions in
experimental animal (Buzsaki, 2002) and humans (Lega et al.,
2012). Therefore, it would be important to test semagacestat if
it impacts physiological theta oscillation during particular behav-
iors and/or cognitive processes, as it could contribute to our
understanding its mode of action for worsening AD symptoms
in patients.
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